89 results
Page 3 of 5
8-K
EX-99.1
owfu5l59 sqxqjdl
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
424B5
oz6u857wg8jib65rnk
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
pua5sg47 t8diy
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
wszil 5zpfc
2 Mar 20
Other Events
7:05am
8-K
EX-99.1
bcv catnwv416505rmo7
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
guud uo5c6rin
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
EX-99.2
i15mag7
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.1
6ezttzu
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
if2ex8yi
6 Aug 19
Results of Operations and Financial Condition
7:13am
PRE 14A
798w1jouc
2 Apr 19
Preliminary proxy
4:29pm